|Place of Origin:||China|
|Brand Name:||Senwayer Brand|
|Certification:||ISO, 9001, USP|
|Model Number:||Q/WHDS 0201-2013|
|Minimum Order Quantity:||1grams|
|Price:||Discount is possible if your order is big enough|
|Packaging Details:||10g, 20g, 50g , 100g, 500g. 1kg, 10kg|
|Delivery Time:||within 2 working days|
|Payment Terms:||T/T in advance, Money Gram, Western Union, Bank Transfer.|
|Model:||41100-52-1||Apparence:||White Or White-like Crystal Powder|
|Grade:||Pharma Grade||Stock:||Enough Stock|
pharmaceutical raw material,
chemical raw material
Antiparkinsonian / Antispasmodic Raw Materials Memantine Hydrochloride HCl 41100-52-1
English name:Memantine hydrochloride
Alias:1.3-Dimethylaminoadamantane hydrochloride；3.5-Dimethyl-1-aminoadamantane hydrochloride
Chemical name:3,5-Dimethyltricyclo(18.104.22.168(3.7)) decan-1-amine hydrochloride
Appearance:white or white-like crystal powder
Packing:packed according to the requirements of the clients
Amorphous crystalline, Melting point: 340° Decomposition. 2, Hydrous crystalline: Melting point: 260--270°.
Memantine HCL is an oral medication for the treatment of moderate to severe dementia associated with Alzheimer's. Memantine HCL's effects are independent of acetylcholine and acetylcholinesterase.
It is believed that too much stimulation of nerve cells by glutamate may be responsible for the degeneration of nerves that occurs in some neurological diseases such as Alzheimer's disease. Glutamate is produced and released by nerve cells in the brain. The released glutamate then travels to nearby nerve cells where it attaches to a receptor on the surface of the cells called the N-methyl-D-aspartate (NMDA) receptor.
Memantine HCL blocks this receptor and thereby decreases the effects of glutamate. It is thought that by blocking the NMDA receptor and the effects of glutamate, memantine may protect nerve cells from excess stimulation by glutamate.
Memantine hydrochloride is a kind of pharmaceutical raw materials, into a tablet called "easy times Shen, the product should be on the diagnosis and treatment of Alzheimer type dementia experienced prescription and guide the patients to use. There are patients with medication on time to supervise the case of starting treatment of caregivers. Dementia should be diagnosed in accordance with current diagnostic criteria and guidelines.